LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

Search

Pulmatrix Inc

Закрыт

6.39 5.45

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

6.06

Макс.

6.47

Ключевые показатели

By Trading Economics

Доход

601K

-2M

Продажи

-363K

3K

Прибыль на акцию

-0.544

Рентабельность продаж

-66,200

Сотрудники

2

EBITDA

705K

-2M

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-3.4M

23M

Предыдущая цена открытия

0.94

Предыдущая цена закрытия

6.39

Pulmatrix Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

15 мая 2025 г., 22:52 UTC

Отчет
Главные движущие силы рынка

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 мая 2025 г., 20:37 UTC

Главные новости
Отчет

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 мая 2025 г., 00:00 UTC

Обсуждения рынка

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 мая 2025 г., 23:47 UTC

Обсуждения рынка

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 мая 2025 г., 23:38 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

15 мая 2025 г., 23:38 UTC

Обсуждения рынка

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 мая 2025 г., 23:14 UTC

Главные новости

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 мая 2025 г., 22:46 UTC

Главные новости
Приобретения, слияния, поглощения

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 мая 2025 г., 22:46 UTC

Приобретения, слияния, поглощения

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 мая 2025 г., 22:46 UTC

Приобретения, слияния, поглощения

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 мая 2025 г., 22:46 UTC

Приобретения, слияния, поглощения

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 мая 2025 г., 21:58 UTC

Отчет

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 мая 2025 г., 21:24 UTC

Отчет

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 мая 2025 г., 20:56 UTC

Обсуждения рынка

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 мая 2025 г., 20:54 UTC

Обсуждения рынка
Отчет

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 мая 2025 г., 20:54 UTC

Отчет

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 мая 2025 г., 20:51 UTC

Отчет

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 мая 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

15 мая 2025 г., 20:50 UTC

Приобретения, слияния, поглощения

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 мая 2025 г., 20:50 UTC

Отчет

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 мая 2025 г., 20:47 UTC

Отчет

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 мая 2025 г., 20:47 UTC

Отчет

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 мая 2025 г., 20:47 UTC

Отчет

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 мая 2025 г., 20:47 UTC

Отчет

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 мая 2025 г., 20:37 UTC

Отчет

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 мая 2025 г., 20:37 UTC

Отчет

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 мая 2025 г., 20:37 UTC

Отчет

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 мая 2025 г., 20:37 UTC

Отчет

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 мая 2025 г., 20:26 UTC

Главные новости

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 мая 2025 г., 20:25 UTC

Отчет

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Pulmatrix Inc Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

0

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.